StockNews.AI
BDMD
StockNews.AI
148 days

Baird Medical Wins "Most Valuable Investment Award" for AI Tumor Ablation Surgical Robot

1. BDMD received 'Most Valuable Investment Award' at China Medical Innovation Competition. 2. Award recognizes BDMD's AI Tumor Ablation Surgical Robot's potential impact on healthcare. 3. Baird Medical focuses on advancing minimally invasive technologies and precision healthcare. 4. Company is expanding its market presence in over 20 countries globally. 5. Strategic collaborations will enhance development of AI surgical robots.

9m saved
Insight
Article

FAQ

Why Bullish?

This award enhances BDMD's visibility and credibility, potentially attracting more investors and partners. Historical awards in this sector have led to price upticks as investor confidence increases.

How important is it?

The award significantly boosts BDMD's reputation and market position, impacting price positively. As BDMD progresses with its AI technology, the potential for increased revenues and improved market sentiment becomes more palpable.

Why Long Term?

The recognition could lead to sustained growth as BDMD continues expanding its product offerings. Previous similar awards led companies to secure more business in the medium to long term.

Related Companies

AAPLAMZNTROWTMDMDT
, /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company") has been honored with the "Most Valuable Investment Award" at the 10th China Medical Industry Innovation Competition, recognizing its groundbreaking AI Tumor Ablation Surgical Robot. Most Valuable Investment Award The China Medical Industry Innovation Competition is a premier industry event recognizing cutting-edge medical technologies with high investment potential. The competition highlights breakthrough innovations poised to transform healthcare, with a focus on advancing medical science and improving patient outcomes. This award underscores Baird Medical's leadership in AI-driven tumor ablation technology. The AI Tumor Ablation Surgical Robot is designed to enhance precision, automation, and real-time decision-making in microwave ablation (MWA), aiming to transform interventional oncology. "This recognition reaffirms our commitment to advancing AI-powered surgical solutions," said Haimei Wu, Chairwoman of Baird Medical. "We believe our innovation will set new standards in tumor ablation, improving patient outcomes globally." Baird Medical remains dedicated to accelerating the development and commercialization of its AI Tumor Ablation Surgical Robot, reinforcing its position in minimally invasive technology.About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:Eric Huang, PR LiaisonBaird Medical Investment Holdings Ltd.Phone: +1 (888) 508-6228Email: [email protected]SOURCE BDMD WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News